Biotherapy of cancer by anti-EGFR monoclonal antibody.
- Author:
Jing WANG
1
;
Zhi-Yun MENG
;
Sou-Ting FU
;
Gui-Fang DOU
Author Information
1. Key Laboratory of Pharmacokinetics, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
pharmacokinetics;
therapeutic use;
Antibodies, Monoclonal, Humanized;
Antineoplastic Agents;
therapeutic use;
Cetuximab;
Humans;
Neoplasms;
therapy;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors;
immunology
- From:
Journal of Experimental Hematology
2007;15(5):1135-1138
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti-tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti-EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed.
